Mersana Therapeutics
2001
FOUNDED
PUBLIC
STATUS
81-90
EMPLOYEES
MRSN
STOCK SYMBOL
$8.05
SHARE PRICE
(As of Friday Closing)
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.
Website
Formerly Known As
Nanopharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 840 Memorial Drive
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Mersana Therapeutics’s full profile, request a free trial.
Mersana Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.32 - $8.93 | $365M | $7.61 | -$1.25 | 369K | 45.3M |
Mersana Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | (43,935) | 8,525 | 334,910 | |
| Revenue | 43,270 | 10,594 | 17,545 | 25,171 |
| EBITDA | (35,069) | (64,398) | (38,689) | (13,166) |
| Net Income | (34,394) | (64,257) | (38,707) | (13,700) |
| Total Assets | 121,655 | 78,502 | 130,715 | 105,087 |
| Total Debt | 8,239 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Mersana Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Mersana Therapeutics‘s full profile, request access.
Request full access to PitchBookMersana Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Mersana Therapeutics‘s full profile, request access.
Request full access to PitchBookMersana Therapeutics Competitors (40)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 00000 0000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 00000000 | 000.00 |
| 000 0000000000000 | Venture Capital-Backed | Chester, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
Mersana Therapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Mersana Therapeutics‘s full profile, request access.
Request full access to PitchBookMersana Therapeutics Executive Team (18)
8 Former Executives
You’re viewing 5 of 18 executives. Get the full list »Mersana Therapeutics Board Members (17)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Andrew Hack Ph.D | Self | Board Member | 000 0000 | |
| Anna Protopapas | Mersana Therapeutics | Chief Executive Officer & Board Member | 000 0000 | |
| David Mott | Self | Chairman & Board Member | 000 0000 | |
| Kristen Hege MD | Self | Board Member | 000 0000 | |
| Lawrence Alleva | Self | Board Member | 000 0000 |
12 Former Board Members
You’re viewing 5 of 17 board members. Get the full list »